SOUTHWESTERN INTERNAL-MEDICINE CONFERENCE - PROSTAGLANDINS AND GASTRIC-ULCERS - FROM SEMINAL-VESICLE TO MISOPROSTOL (CYTOTEC)

Misoprostol (Cytotec, G.D. Searle and Company, Chicago, IL) is the first of a new class of orally administered prostaglandin analog drugs to be marketed in the United States. Misoprostol was approved for the prevention of gastric mucosal ulcers associated with nonstearoidal anti-inflammatory drugs (NSAIDS) in high-risk patients. This represents a potentially important development in the pharmacotherapy of peptic ulcer disease. The purposes of this article are to review (1) the biochemistry, physiology, and pharmacology of prostaglandins, especially those synthesized by the stomach; (2) the potential role of prostaglandin deficiency in the pathophysiology of gastric ulcer disease; and (3) the role of prostaglandin analogs in the prevention and therapy of gastric ulcer disease and in other conditions. As the mechanism of action of these new drugs differs from that of the histamine H2-receptor antagonists (H2-blockers), prostaglandin analogs will, whenver possible, be compared with the H2-blockers [cimetidine (Tagamet), ranitidine (Zantac), nizatidine (Axid) and famotidine (Pepcid)], currently the cornerstone of peptic ulcer therapy in this country.